Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VXCO-100 in Adults
NCT05938075Phase 1Completed
- Sponsor
- Vaccine Industrial Company
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of VXCO-100 in coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) (4 arms), sponsored by Vaccine Industrial Company. Primary endpoints: Number and percentage of participants with solicited local adverse events at 7 days, Number and percentage of participants with solicited systemic adverse events at 7 days and 2 more. Started Aug 2023; status: completed.
02
Drugs
VXCO-100
03
Conditions
coronavirus disease 2019 (COVID-19)severe acute respiratory syndrome (SARS)
Beyond the preview
Go deeper on NCT05938075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938075.